Trial Profile
CCR5 Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
- Indications HIV-1 infections
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- Acronyms CADIRIS
- 27 Mar 2013 Status changed from active, no longer recruiting to completed.
- 06 Mar 2013 Results presented at the 20th Conference on Retroviruses and Opportunistic Infections.
- 08 Feb 2012 Planned End Date changed from 1 Jan 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.